Age-related maculopathy and age-related macular degeneration are
common traits that result from the complex interaction of environmental
and hereditary risk factors. Some risk factors, such as cigarette
smoking and increasing age, are well established by multiple
epidemiologic studies.
30 31 32 Other risk factors such as
nutrition and race are strongly suspected to play a role, along with
gender, light exposure, and cardiovascular disease, for which the
supporting data are more equivocal.
31 32 33 Genetic
susceptibility to visual loss from AMD has long been suspected,
especially because many patients note that AMD seems to “run in the
family.” This notion is supported by an epidemiologic study that
demonstrated an age-adjusted 2.4-fold elevated relative risk of AMD in
first-degree relatives of patients with AMD.
27 Definitive
demonstration of an inherited risk factor for AMD has been elusive,
however. Human molecular genetics has had by far the most success in
defining the genetic etiology of ophthalmic diseases with a clear
monogenic hereditary basis and well-defined diagnostic criteria.
Genetic studies on retinitis pigmentosa,
34 retinoblastoma,
35 and color blindness
36 are
excellent examples of such successes. Determining genetic factors
involved in late-onset common ophthalmic disorders with variable
clinical presentations such as glaucoma and AMD has been a far more
evanescent goal.
A cornerstone methodology for studying the genetics of human diseases
is the collection and characterization of multigenerational kindreds
with the disorder. This approach is quite problematic for AMD, however.
As a disease of the elderly, the affected proband’s parents are
usually dead, siblings are often dead or in widely scattered locations,
and offspring are typically too young to manifest symptoms. Even with
the ascertainment of a large kindred with AMD, the researcher is faced
with substantial challenges, due to the high prevalence of the disease,
its variable expressivity, and its apparent multifactorial etiology.
Unlike a relatively uncommon disease such as retinitis pigmentosa, in
which affected family members almost certainly have identical genetic
defects, the situation is not as simple for AMD. Interaction of
multiple AMD-associated alleles in many genes may be needed for
increased susceptibility within a particular family. Thus, it cannot be
assumed that affected siblings must have the same AMD-associated
allele. The broad spectrum of clinical presentation of AMD ranging from
exudative changes to geographic atrophy raises the question of whether
AMD is truly one disorder or actually represents a multitude of
diseases with different genetic etiologies, and the variable
presentation and progression of AMD often requires an arbitrary
delineation of which individuals are or are not affected. The interplay
of nongenetic risk factors for AMD, such as smoking history,
nutritional status, and light exposure complicates genetic studies
because even if an individual has inherited a putative AMD
susceptibility allele, the disease may not manifest if a protective
lifestyle has been practiced. Also, age must be considered a factor,
because a few soft and hard drusen in the macula of a 95-year-old
patient may be normal, whereas the same findings in a 45-year-old
patient may be considered the first signs of AMD.
Even if linkage is established to a chromosomal locus, it is often a
long and arduous task to determine the actual genetic defect, because
the chromosomal locus may encompass dozens of genes. Significant
linkage has been reported only recently in one AMD family at locus
1q25-31,
37 and it is likely that further progress with
this approach will continue to be slow.
38
The genetic investigation of AMD is amenable to the “candidate
disease” approach. AMD shares phenotypic similarities to a number of
hereditary diseases of the macula, and as the genetic bases for these
diseases are ascertained, cohorts of patients with AMD can then be
screened to determine whether comparable mutations are involved in the
pathogenesis of AMD.
10 Stargardt disease (STGD1) is the
most promising candidate disease for AMD. This autosomal recessive
disorder is the most common early-onset macular dystrophy encountered
in clinical practice (estimated frequency, 1 in 10,000).
4 It is characterized by macular atrophy and drusen-like flecks with
associated central visual loss that typically occurs in the second or
third decade of life but with earlier and later onsets well documented.
The retinal pigment epithelium (RPE) accumulates large enough amounts
of lipofuscin to exhibit a dark choroid on fluorescein angiography.
Exudative complications are rare.
10
If mutations in both alleles of
ABCR can lead to protein
dysfunction severe enough to manifest as an early-onset macular
dystrophy such as STGD1, is it possible that a mutation in one
ABCR allele could lead to moderate dysfunction sufficient to
cause late-onset macular degeneration such as AMD? Our findings of an
elevated frequency of amino acid–changing
ABCR variants in
patients with AMD relative to age-matched control subjects supports
this hypothesis.
14 19 Physiologically, this hypothesis is
tenable. In patients with STGD1, severe
ABCR dysfunction
disrupts vitamin A transport pathways from the outer segment
disks leading to formation of massive amounts of lipofuscin, which
accumulates in the RPE.
2 Less profound disruption of
ABCR function in the heterozygous state acting over a
prolonged period could lead to a similar accumulation of lipofuscin,
albeit at a much slower rate. Indeed, lipofuscin formation is strongly
associated with the progression of AMD,
39 40 and knockout
mouse studies have confirmed that both homozygous and heterozygous
mutations in
ABCR are associated with increasing lipofuscin
accumulation over time, especially when these animals are exposed to
light.
41 42 43
Similarly, as has been demonstrated in other clinical disorders
associated with mutations in
ABCR, this study was not and
could not be designed to detect complex alleles that comprise a
substantive fraction of all
ABCR mutations, especially
because complete sequencing and segregation through at least two
generations could not be performed. However, complex alleles probably
play a greater role in both the structural and physiologic functions of
ABCR than have been appreciated to date, and the
consequences of a single complex mutation in the heterozygote over many
decades are only now being investigated in detail.
4 44 45
When we examined siblings of patients with ABCR variants, we
demonstrated concordance of ABCR genotype with AMD phenotype
in some families, but not in others. Also, when the data from all the
families were pooled, they did not show a statistically significant
correlation between ABCR variants and risk of AMD, possibly
in part because of the relatively small numbers of study participants.
Some elderly siblings had an ABCR variant, but no evidence
of AMD. Other elderly siblings had AMD without having the same ABCR variant as the affected proband.
There are several possible explanations for the variable expressivity
of AMD among those with
ABCR variants. AMD progression in
individuals with
ABCR variants may be strongly influenced by
concomitant environmental risk factors, such as smoking, light
exposure, and diet, that were not examined or controlled in this study.
Our study of the D2177N and G1961E mutations in age-matched
ophthalmoscopically examined control subjects confirms that an
ABCR variant does not by itself confer an AMD phenotype in
all cases, but may increase susceptibility to the complex trait when
large populations are examined.
19
The fact that many siblings have AMD without the same
ABCR variant as the family proband is not unexpected, especially because
there are likely to be other inherited and environmental risk factors
that have not yet been identified that may act alone or in concert with
ABCR alleles to enhance susceptibility to AMD. Depending on
the age of the individual, the risk of having AMD can be quite
substantial. If an individual is over age 70, he or she has a 30% risk
of having AMD or ARM.
31 32 Also, we did not screen for
other
ABCR mutations in the siblings beyond the known
variant of the proband. Thus, the contribution of other possible
ABCR variants in these families is unknown. Because at least
4% of the general population is thought to carry a mutant
ABCR allele,
5 18 this effect may be important.
The combined effects of variable expressivity at the age of
surveillance and high disease prevalence made it unlikely that
statistical significance could be achieved in a study of this size.
This is a recurring problem facing investigators studying other complex
adult-onset multifactorial diseases, such as breast cancer and prostate
cancer.
46 47 Statistical power analysis indicates that we
would need 144 siblings to achieve an 80% power of detecting a
statistically significant elevated risk at
P = 0.05 if
the study population prevalence of AMD is assumed to be 10% and the
elevated risk of AMD conferred by any AMD-associated
ABCR variant is comparable to the approximately threefold elevation in AMD
risk found for the G1961E and D2177N
ABCR variants in the
International
ABCR Consortium Study.
19
Although there is mounting evidence that heterozygous variants in ABCR contribute to AMD susceptibility, we should not expect
consistent concordance of variant alleles with AMD phenotype, because
it is a complex trait influenced by a multitude of other hereditary and
environmental risk factors. Nevertheless, study of the families
reported here has yielded important conclusions: (1) Affected siblings
with the same ABCR variant may have highly concordant
disease phenotypes. For example, all four siblings in kindred K4495
carried the same I1562T mutation, and all four had severe geographic
atrophy in their eighth decade. (2) Exudative AMD, although present in
more than 25% of the original study participants, was rare (<4%)
among family probands found to have ABCR variants.
Similarly, exudative AMD was also found to be uncommon (1/19) in
probands’ siblings possessing the identical ABCR variant.
This correlates well with fact that Stargardt disease is almost
exclusively a nonexudative macular dystrophy.
The authors thank the families described herein for their willing
and continuing cooperation in these investigations; and Missy Dixon,
Jennifer Cote, Sandy Chong, Johann Soults, John Leslie, Jonathan
Seidman, and Christine Seidman for research assistance and advice.